Treatment of benign cold thyroid nodules: a randomized clinical trial of percutaneous laser ablation versus levothyroxine therapy or follow-up

Thyroid. 2007 Mar;17(3):229-35. doi: 10.1089/thy.2006.0204.

Abstract

Aim of the study: To compare clinical and ultrasound (US) changes induced in cold thyroid nodules by US-guided percutaneous laser ablation (PLA) versus follow-up or levothyroxine (LT4) suppressive therapy.

Methods: 62 patients randomly assigned to a single PLA (Group 1), LT4 (Group 2), or follow-up (Group 3). Entry criteria: euthyroid patients with a solid thyroid nodule >5 mL and benign cytological findings.

Treatment: Group 1: PLA was performed with a 1.064 mum neodymium yttrium-aluminum-garnet laser with output power of 3 W for 10 minutes; Group 2: the LT4 dose was adjusted to induce thyrotropin suppression; Group 3: no treatment.

Results: In Group 1 a significant nodule reduction was found 6 and 12 months after PLA (delta volume: -42.7 +/- 13.6%; p = 0.001). A reduction >50% was found in 33.3% of cases. In Group 2 a nonsignificant nodule shrinkage was observed. A nonsignificant volume increase was observed in Group 3. Improvement of local symptoms was registered in 81.2% of patients in Group 1 vs. 13.3% in Group 2 and 0.0% in Group 3 ( p = 0.001). No complications were noted.

Conclusions: A single PLA induced significant volume reduction and improvement of local symptoms. PLA was more effective than LT4. Follow-up was associated with nodule growth and progression of local symptoms. PLA should be considered a potential mini-invasive alternative to surgery in symptomatic patients with benign cold thyroid nodules.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Administration, Cutaneous
  • Adult
  • Female
  • Humans
  • Lasers*
  • Male
  • Middle Aged
  • Odds Ratio
  • Prospective Studies
  • Receptors, Thyroid Hormone / metabolism
  • Thyroid Gland / drug effects
  • Thyroid Gland / physiopathology
  • Thyroid Nodule / therapy*
  • Thyrotropin / biosynthesis
  • Thyroxine / therapeutic use*
  • Treatment Outcome

Substances

  • Receptors, Thyroid Hormone
  • Thyrotropin
  • Thyroxine